OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in immunology
2020;11 517290.

Challenges of Developing Novel Vaccines With Particular Global Health Importance.

Penny M Heaton
Author Information
  1. Penny M Heaton: Bill & Melinda Gates Medical Research Institute, Cambridge, MA, United States.
PMID: 33162972 DOI: 10.3389/fimmu.2020.517290

Abstract

Six of the top ten leading causes of death in low resource settings could potentially be prevented by vaccination. Development of vaccines for individuals in these populations is difficult because of the biological complexity of the prevalent pathogens and the challenges inherent to development of any vaccine. This review discusses those challenges and promising advances to address them and highlights recent progress in development of vaccines against several pathogens of interest.

Keywords

HIV/AIDS infectious diseases low resource areas malaria respiratory syncytial virus shigella tuberculosis vaccine development

References

  1. Dev Biol (Basel). 2002;110:25-9 [PMID: 12477303]
  2. Clin Pharmacol Ther. 2018 Dec;104(6):1062-1073 [PMID: 30099743]
  3. Annu Rev Immunol. 2013;31:475-527 [PMID: 23516984]
  4. Clin Vaccine Immunol. 2016 Dec 5;23(12):904-907 [PMID: 27707764]
  5. Future Microbiol. 2018 Aug;13:1193-1208 [PMID: 30117744]
  6. N Engl J Med. 2012 Apr 5;366(14):1275-86 [PMID: 22475592]
  7. N Engl J Med. 2011 Nov 17;365(20):1863-75 [PMID: 22007715]
  8. PLoS One. 2016 Oct 20;11(10):e0164789 [PMID: 27764150]
  9. Lancet. 2013 Nov 23;382(9906):1700-1 [PMID: 24239252]
  10. Cell Rep. 2016 Jan 5;14(1):68-81 [PMID: 26725120]
  11. Int J Tuberc Lung Dis. 2010 Apr;14(4):406-12 [PMID: 20202297]
  12. JAMA. 1994 Mar 2;271(9):698-702 [PMID: 8309034]
  13. Front Immunol. 2018 Dec 19;9:3006 [PMID: 30619355]
  14. Nat Med. 2018 Feb;24(2):130-143 [PMID: 29334373]
  15. Tuberculosis (Edinb). 2016 Dec;101:174-190 [PMID: 27865390]
  16. AIDS. 2010 Mar 13;24(5):675-85 [PMID: 20118767]
  17. Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents [PMID: 19136431]
  18. JAMA. 2019 Sep 10;: [PMID: 31503276]
  19. Lancet. 2017 Sep 2;390(10098):946-958 [PMID: 28689664]
  20. N Engl J Med. 2009 Dec 3;361(23):2209-20 [PMID: 19843557]
  21. N Engl J Med. 2019 Dec 19;381(25):2429-2439 [PMID: 31661198]
  22. F1000Res. 2019 May 2;8: [PMID: 31105933]
  23. N Engl J Med. 2018 Jul 12;379(2):138-149 [PMID: 29996082]
  24. Lancet. 1997 Jan 18;349(9046):155-9 [PMID: 9111538]
  25. Cell. 2016 Oct 6;167(2):433-443.e14 [PMID: 27667685]
  26. Vaccine. 2015 Nov 25;33(47):6420-9 [PMID: 26320417]
  27. Vaccine. 2019 Aug 7;37(34):4778-4783 [PMID: 31358238]
  28. Am J Epidemiol. 1969 Apr;89(4):422-34 [PMID: 4305198]
  29. N Engl J Med. 2018 Oct 25;379(17):1621-1634 [PMID: 30280651]
  30. Lancet. 2015 Jul 4;386(9988):31-45 [PMID: 25913272]

MeSH Term

Global Health
Humans
Vaccination
Vaccines

Chemicals

Vaccines
Journal Article Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 15

Word Cloud

Created with Highcharts 10.0.0developmentlowresourcevaccinespathogenschallengesvaccineSixtoptenleadingcausesdeathsettingspotentiallypreventedvaccinationDevelopmentindividualspopulationsdifficultbiologicalcomplexityprevalentinherentreviewdiscussespromisingadvancesaddresshighlightsrecentprogressseveralinterestChallengesDevelopingNovelVaccinesParticularGlobalHealthImportanceHIV/AIDSinfectiousdiseasesareasmalariarespiratorysyncytialvirusshigellatuberculosis

Similar Articles

Cited By